Only 29% of people with diabetes report that their doctors ask them for input for their own treatment plans

Novo NordiskResults from the global Diabetes Attitudes, Wishes and Needs 2 study (DAWN2™) presented today at a symposium during the World Diabetes Congress of the International Diabetes Federation (IDF), show that only 29% of people with diabetes report that their healthcare team ask for their input when making their treatment plans. Furthermore, only 33% said they were encouraged by their healthcare professional to ask questions in the consultation.

These results are surprising, given the importance of active involvement of people with diabetes in their own treatment and care. In fact, 84% of healthcare professionals who took part in the study said it would be helpful if their patients prepared questions in advance of the consultation[1].

"People with diabetes who feel supported and capable of self-managing their condition are more likely to have a successful treatment outcome and therefore have the opportunity to live a better life with diabetes," explained Ingrid Willaing, head of Education Research at the Steno Diabetes Center and lead national investigator for DAWN2™ in Denmark, during her symposium presentation. "The DAWN2™ study highlights that far too few people with diabetes are supported to take an active role."

To help break down communication barriers and misconceptions about diabetes treatments and thereby improve effective self-management of type 2 diabetes, a theatre play called "Getting Straight to the Point" was held at the Congress on 4 December. Here, a panel of leading diabetes experts called for both healthcare professionals and people with type 2 diabetes to create opportunities for open dialogue, shared decision-making and active engagement for better physical and emotional outcomes.

A series of other global DAWN2™ results were announced during the Congress highlighting the insufficiencies relating to quality of life with diabetes, support for families, access to diabetes education and psychosocial support, positive awareness of diabetes in society and attention to the special needs of vulnerable populations with diabetes.

"The DAWN2™ study calls for united efforts across stakeholders and nations to advance a person-centred approach to improve prevention, care, education and support for people with diabetes and their families," says Sir Michael Hirst, president of the International Diabetes Federation.

DAWN2™ represents the voices of more than 15,000 people with diabetes, their family members and healthcare professionals in 17 countries across 4 continents.

About DAWN2™
DAWN2™ is a global Novo Nordisk initiative conducted in collaboration with the IDF, the International Alliance of Patients’ Organizations (IAPO), the Steno Diabetes Center and a range of other national, regional and global partners. The DAWN2™ results highlight opportunities for improving diabetes care, education and community support by putting people with diabetes and their families centre stage. The DAWN2™ study will be used internationally and nationally to facilitate dialogue among patient organisations, healthcare professionals and other key stakeholders to develop action plans for improvement of the lives of people with diabetes.

About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately 37,000 employees in 75 countries, and markets its products in more than 180 countries.

1. I. Willaing, DAWN2™ Study Results: Involvement and Education. Oral Lecture, DAWN2™ Symposium, 5 December 2013, World Diabetes Congress of the International Diabetes Federation (IDF).

Most Popular Now

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

MSD is looking for a digital health solution to em…

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The sol...

Lilly submits New Drug Application to the FDA for …

Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

Scorpion venom to shuttle drugs into the brain

The Peptides and Proteins lab at the Institute for Research in Biomedicine (IRB Barcelona) has published a paper in Chemical Communications describing the capacity of a s...

Abbott recommends rejection of below-market mini-T…

Abbott (NYSE: ABT) received notice of an unsolicited mini-tender offer by Baker Mills LLC (Baker Mills) to purchase up to 60,000 Abbott common shares, representing approx...

AstraZeneca to divest US Synagis rights to Sobi

AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncyt...